ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance
We report on 8 patients with ankyrin repeat domain 26 (ANKRD26)-related thrombocytopenia 2 (ANKRD26-RT) with elevated bone marrow myeloblasts and dysmegakaryopoiesis, without somatic genetic abnormalities or progression to malignancy during long-term observation, findings which may constitute inherent ANKRD26-RT biology rather than progression to myeloid malignancy.
Authors
- Jason X. Cheng (ORCID: https://orcid.org/0000-0002-4626-770X)
- Lara Wahlster (ORCID: https://orcid.org/0000-0001-8409-7580)
- Nina Weichert‐Leahey (ORCID: https://orcid.org/0000-0002-0351-3018)
- Alan Cantor (ORCID: https://orcid.org/0000-0002-5136-028X)
- Michael W. Drazer (ORCID: https://orcid.org/0000-0002-8171-4106)
- Lev Gorfinkel (ORCID: https://orcid.org/0000-0002-8781-2276)
- Akiko Shimamura (ORCID: https://orcid.org/0000-0002-4683-9958)
- R. Grant Rowe (ORCID: https://orcid.org/0000-0003-3620-2950)
- Alan D. Michelson (ORCID: https://orcid.org/0000-0002-1746-4819)
- Franziska Wachter (ORCID: https://orcid.org/0000-0001-9185-3612)
- Christopher R. Reilly (ORCID: https://orcid.org/0000-0002-9551-7533)
- Lucy A. Godley (ORCID: https://orcid.org/0000-0003-1914-9158)
- Jacob R. Bledsoe (ORCID: https://orcid.org/0000-0002-2387-5462)
- Karyn Brundige
- Jared H. Rowe (ORCID: https://orcid.org/0000-0002-4223-4433)
- Geraldine S. Pinkus
- Luana Messa
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Harvard University (US)
- University of Chicago (US)
- Northwestern Memorial Hospital (US)
- Dana-Farber Cancer Institute (US)
- Northwestern Medicine (US)
- Boston Children's Museum (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- Blood
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1182/blood.2024027368
- Citations
- 2
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54